A United States District Court has finalized a significant financial penalty against Apple Inc., ruling that the technology giant must pay an additional $184.2 million in prejudgment interest to medical technology firm Masimo. This ruling follows a prior jury verdict that found Apple had infringed upon Masimo’s patented pulse oximetry technology, used to measure blood oxygen levels in various iterations of the Apple Watch. With the addition of this interest, the total financial obligation for Apple in this specific litigation has climbed to approximately $818.5 million, marking one of the most substantial patent-related financial hits to the company in recent years.
The decision, handed down by Judge James Selna of the U.S. District Court for the Central District of California, underscores the legal principle that patent holders must be fully compensated for the time-value of money lost during the period of infringement. Beyond the lump sum, the court also mandated that Apple pay postjudgment interest at a rate of 4% on the total amount, effective from July 20, 2024, until the judgment is fully satisfied.
The Genesis of the Dispute: Innovation and Allegation
The legal battle between Apple and Masimo is not merely a dispute over royalties but a complex saga involving allegations of corporate poaching, trade secret misappropriation, and the aggressive pursuit of health-tracking dominance. Masimo, a company founded by Joe Kiani in 1989, is renowned for its Signal Extraction Technology (SET), which allows pulse oximeters to provide accurate readings even when a patient is moving or has low perfusion. This technology became the gold standard in hospitals worldwide.
According to court filings and testimony, the relationship between the two companies began amicably in 2013. Apple reportedly contacted Masimo to discuss a potential collaboration or even an acquisition. During these meetings, Masimo shared confidential information regarding its non-invasive blood oxygen monitoring sensors. However, the partnership never materialized. Instead, Apple began hiring key personnel from Masimo and its spinoff, Cercacor, including Masimo’s Chief Medical Officer and Cercacor’s Chief Technology Officer.
By 2020, Masimo filed its first lawsuit against Apple, coinciding with the release of the Apple Watch Series 6, the first model to feature blood oxygen monitoring. Masimo alleged that Apple had not only infringed on its patents but had also stolen trade secrets to develop the sensor. While the trade secret portion of the litigation faced various hurdles—including a mistrial in 2023—the patent infringement claims gained significant traction.
The Mechanical and Legal Nuances of Pulse Oximetry
To understand the magnitude of the infringement, one must look at the technology involved. Pulse oximetry works by emitting light at specific wavelengths through the skin. Oxygenated and deoxygenated hemoglobin absorb light differently; by measuring the light that passes through or reflects back, a device can calculate the percentage of oxygen in the blood.
Masimo’s patents covered specific methods of filtering out "noise" (such as physical movement) to ensure the accuracy of these readings. The jury found that Apple’s implementation of this feature in the Apple Watch utilized Masimo’s patented innovations without a license. This led to a $634 million damages award, calculated as a "running royalty" based on the number of infringing Apple Watch units sold since the technology’s introduction.
The Battle Over Prejudgment Interest
The recent ruling focused specifically on the "prejudgment interest"—a legal mechanism designed to ensure that a plaintiff is not penalized for the duration of a trial. In patent law, the objective is to place the patent owner in the same financial position they would have occupied had the infringer entered into a reasonable royalty agreement at the time the infringement began.
Masimo argued that because the $634 million award was based on a per-watch royalty starting from the initial date of infringement, the company had been deprived of the use of that capital for years. Masimo’s legal team initially sought an interest rate of 7%, citing the California Constitution’s default rate for judgments. This would have added a staggering $242.7 million to the total.
Apple’s defense team countered that the $634 million jury award was already "staggering" and sufficient to compensate Masimo. They argued that adding nearly a quarter-billion dollars in interest would constitute a "windfall" for Masimo rather than a corrective measure. Apple proposed a much lower interest rate based on Treasury bill yields, which would have resulted in an interest payment of approximately $114.5 million.
Judge Selna ultimately took a middle path. He rejected Apple’s argument that the size of the jury award should preclude or limit interest, noting that the law requires full compensation regardless of the base amount’s scale. However, he also declined Masimo’s 7% request. Instead, the judge utilized Masimo’s actual borrowing costs during the period of infringement as the benchmark. By accounting for annual compounding and Masimo’s corporate credit profile, the court arrived at the $184.2 million figure.
Timeline of Key Events in the Apple-Masimo Litigation
The path to this $818.5 million judgment has been marked by several critical milestones:
- 2013: Apple and Masimo hold initial meetings regarding health sensor integration.
- 2014-2016: Apple hires several high-level engineers and executives from Masimo.
- January 2020: Masimo sues Apple in federal court for patent infringement and trade secret theft.
- September 2020: Apple releases the Watch Series 6 with pulse oximetry.
- January 2023: The U.S. International Trade Commission (ITC) rules that Apple infringed on Masimo’s patents.
- May 2023: A federal judge declares a mistrial in the trade secrets case after a jury fails to reach a unanimous verdict.
- October 2023: The ITC issues an exclusion order, effectively banning the import of infringing Apple Watches into the U.S.
- December 2023: Apple briefly pauses sales of the Apple Watch Series 9 and Ultra 2 in the U.S. to comply with the ITC order.
- January 2024: Apple begins selling modified versions of its watches with the pulse oximetry feature disabled via software to circumvent the import ban.
- July 2024: The court calculates final damages and interest, resulting in the current $818.5 million total.
Broader Implications for the Tech and Medical Industries
The ruling against Apple sends a powerful signal to the "Big Tech" sector regarding the risks of entering the highly regulated and patent-dense medical device market. For years, companies like Apple, Google, and Amazon have sought to pivot toward health and wellness, viewing the data generated by wearables as a primary growth engine. However, this case demonstrates that the "move fast and break things" ethos of Silicon Valley can collide disastrously with the entrenched intellectual property of specialized MedTech firms.
For Masimo, the victory is both financial and symbolic. CEO Joe Kiani has been vocal about what he describes as Apple’s "predatory" hiring practices and intellectual property "bullying." In public statements, Kiani has framed the litigation as a fight for the integrity of the American innovation ecosystem, arguing that if a company as large as Apple can take technology from smaller innovators without consequence, the incentive to invent will vanish.
Apple, conversely, maintains that it develops its technology independently and that Masimo is using the legal system to stifle competition from a superior consumer product. The financial hit, while significant, represents a small fraction of Apple’s nearly $100 billion in annual net income. However, the reputational cost and the forced disabling of a key health feature in its flagship wearable are more difficult to quantify.
What Lies Ahead: Appeals and Market Adjustments
The legal saga is far from over. Apple is expected to appeal the judgment to the U.S. Court of Appeals for the Federal Circuit. Historically, Apple has been aggressive in its appellate strategy, often succeeding in reducing damage awards or overturning infringement findings. If the appeal proceeds, the $818.5 million payment could be stayed for months or even years.
Furthermore, the "software fix" Apple implemented—disabling the blood oxygen feature for new U.S. customers—remains a point of contention. Masimo has argued that a software disablement is insufficient to bypass the patents, as the hardware remains capable of the function. This could lead to further rounds of litigation regarding the "design-around" measures Apple has taken.
In the consumer market, the ruling has created a bifurcated experience for Apple Watch users. Those who purchased their devices before the ban or who live outside the United States continue to enjoy blood oxygen monitoring. New buyers in the U.S., however, are purchasing a hardware-identical device with a deactivated sensor, a situation that could persist until the patents expire or a settlement is reached.
The $818.5 million judgment serves as a landmark in the intersection of consumer electronics and medical technology. It highlights the rising costs of patent litigation in the age of the "smart" health device and reaffirms the judiciary’s commitment to ensuring that patent holders are made whole, not just for the theft of their ideas, but for the time it takes to prove that theft in a court of law. As Apple prepares its next legal move, the tech industry at large will be watching closely, recognizing that the price of innovation is increasingly being set in the courtroom.
